SCHEMBL6491571

SCHEMBL6491571

CCOc1ccc(Cn2c(CC)nc3ccc(Br)nc32)c(Cl)c1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 1/20 0.38
LMNA P02545 4/20 0.35
SMN1; SMN2 Q16637 3/20 0.35
ALDH1A1 P00352 3/20 0.35
HPGD P15428 3/20 0.35
KDM4E B2RXH2 2/20 0.35
NPSR1 Q6W5P4 1/20 0.35
TP53 P04637 4/20 0.35
MAPT P10636 4/20 0.35
F2RL3 Q96RI0 1/20 0.34
HTR6 P50406 1/20 0.34
POLB P06746 1/20 0.33
TSHR P16473 3/20 0.33
NPC1 O15118 2/20 0.33
RAB9A P51151 2/20 0.33
HSD17B10 Q99714 2/20 0.33
USP2 O75604 1/20 0.33
NFKB1 P19838 1/20 0.33
NFKB2 Q00653 1/20 0.33
RELA Q04206 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6499926 0.92 SMN1; SMN2 (0.38) LMNASMN1; SMN2ALDH1A1HPGDKDM4E
SCHEMBL6504961 0.90 SMN1; SMN2 (0.41) LMNASMN1; SMN2ALDH1A1HPGDKDM4E
SCHEMBL6494971 0.85 HPGD (0.38) HPGDF2RL3ALOX5AP
SCHEMBL6492718 0.83 KDM4E (0.39) LMNASMN1; SMN2ALDH1A1HPGDKDM4E
SCHEMBL6489800 0.83 LMNA (0.37) KMT2ALMNASMN1; SMN2ALDH1A1HPGD
SCHEMBL6504657 0.82 KDM4E (0.39) KMT2ALMNAKDM4ETP53MAPT
SCHEMBL6503371 0.78 PDE2A (0.41) LMNASMN1; SMN2ALDH1A1HPGDKDM4E
SCHEMBL6501797 0.76 DHODH (0.39) KMT2ALMNASMN1; SMN2ALDH1A1HPGD
SCHEMBL9319006 0.76 LMNA (0.47) LMNASMN1; SMN2ALDH1A1HPGDKDM4E
SCHEMBL6495121 0.75 PPARG (0.51)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6890934-B2 Sulfonamide compounds and uses thereof as medicines FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2005-05-10 US disclosed
US-20030171396-A1 Sulfonamide compounds and uses thereof as medicines FUJISAWA PHARMACEUTICAL CO. LTD. (JP) 2003-09-11 US disclosed
US-6573274-B1 Treatment of the diseases curable based on a hypoglycemic action, and the diseases curable based on a cGMP-PDE inhibitory action, a smooth muscle relaxing action, a bronchodilating action, a vasodilating action, a smooth muscle FUJISAWA PHARMACEUTICAL CO. LTD. (JP) 2003-06-03 US disclosed
EP-1136492-A1 SULFONAMIDE COMPOUNDS AND USES THEREOF AS MEDICINES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2001-09-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030171396-A1 Sulfonamide compounds and uses thereof as medicines PDE2A, PDE3A, PDE5A KMT2A 1625/4885LMNA 2742/4885SMN1; SMN2 325/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.